Goodpasture’s syndrome (GS) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Goodpasture’s syndrome (GS) is a rare, life-threatening, small vessel vasculitis that is mediated by circulating anti-glomerular basement membrane (anti-GBM) autoantibodies against the NC1 domain of the alpha 3 chain of type IV collagen, targeting capillaries of the kidneys and lungs. It is considered as one of the organ-specific autoimmune diseases that typically presents as rapidly progressive glomerulonephritis (RPGN), accompanied by alveolar hemorrhage with pathology characterized by crescentic glomerulonephritis with classic linear polyclonal immunoglobulin (Ig) G deposits on immunofluorescence staining of the GBM on analysis of kidney biopsy samples. Without prompt diagnosis and treatment, patients with GS can develop organ failure, resulting in significant morbidities and mortality. Patient characteristics included age, sex, race, year of hospitalization, smoking, hemoptysis, and the presence of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, which consisted of granulomatosis polyangiitis, microscopic polyangiitis, and sepsis.
In European and Asian populations, the incidence of
GS is estimated to be 0.5 to 1.8 cases per million population per year and the
prevalence of GS among hospitalized patients in the United States is 10.3 cases
per million hospital admissions.
The competitive
landscape of Goodpasture’s syndrome (GS) includes country-specific approved and
pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of Goodpasture’s
syndrome (GS) across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Goodpasture’s
syndrome (GS) Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
Comments
Post a Comment